Compare Edwards Lifesciences Corporation Common Stock (EW) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Invesco Ltd. — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $83.56 (market cap $48.56B), while Invesco Ltd. trades at $29.67 (market cap $13.28B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 3.7× Invesco Ltd.'s market cap, and Invesco Ltd. pays a 2.86% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | IVZ | |
|---|---|---|
Market Cap | $48.56B | $13.28B |
Volume | 6,520,488 | 3,698,033 |
Sector | Health | Financials |
52-Week High | $95.18 | $33.31 |
52-Week Low | $72.65 | $22.44 |
Enterprise Value | $45.01B | $23.45B |
Typical Hold Time | — | 77 Days |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Invesco (IVZ) trades at $30.50, up 0.39% on the day, with a mixed technical outlook showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $281.7 million for 2025 despite revenue growth to $6.38 billion, with profitability metrics like ROE at -2.97% indicating challenges. Recent news highlights the expansion of its QQQ ETF suite and a dividend declaration, while analyst consensus remains cautiously optimistic with a $33.71 price target.
The outlook for IVZ hinges on reversing negative earnings trends and capitalizing on ETF growth initiatives. Key opportunities include strong asset under management growth and product innovation, but risks persist from competitive pressures and market volatility. Investors should weigh the potential for operational improvement against ongoing profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
